» Articles » PMID: 9160658

Chronic Myelomonocytic Leukemia in Childhood: a Retrospective Analysis of 110 Cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1997 May 15
PMID 9160658
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic myelomonocytic leukemia (CMML) is a rare hematopoietic malignancy of childhood. To define the clinical and hematologic characteristics of the disease, we performed a retrospective analysis of 110 children given the diagnosis CMML irrespective of karyotype. Median age at diagnosis was 1.8 years. Neurofibromatosis type 1 was known in 14% and other clinical abnormalities in 7% of the children. At presentation, the medium white blood count was 35 x 10(9)/L, with a median monocyte count of 7 x 10(9)/L. Karyotypic abnormalities in bone marrow cells were noted in 36% of the patients, whereas 26% of the children had monosomy 7. Children with monosomy 7 did not differ from those with normal karyotype with respect to their clinical presentation. However, they did display some characteristic hematologic features. Of 110 children, 38 received an allogeneic bone marrow transplant (BMT). The probability of survival at 10 years was 0.39 (standard error [SE] = 0.10) for the BMT group and 0.06 (SE = 0.4) for the 72 patients of the non-BMT group. Platelet count, age, and hemoglobin F at diagnosis were the main predicting factors for the length of survival in the non-BMT group. There is a strong need for a broad agreement on nomenclature in children with myelodysplastic syndromes (MDS). We propose here to use the French-American-British classification for MDS in childhood.

Citing Articles

Cancer-independent somatic mutation of the wild-type NF1 allele in normal tissues in neurofibromatosis type 1.

Oliver T, Lawson A, Lee-Six H, Tollit A, Jung H, Hooks Y Nat Genet. 2025; 57(3):515-521.

PMID: 40000831 PMC: 11906363. DOI: 10.1038/s41588-025-02097-2.


Observation and Management of Juvenile Myelomonocytic Leukemia and Noonan Syndrome-Associated Myeloproliferative Disorder: A Real-World Experience.

Lucas B, Connors J, Wang H, Conneely S, Cuglievan B, Garcia M Cancers (Basel). 2024; 16(15).

PMID: 39123476 PMC: 11311611. DOI: 10.3390/cancers16152749.


Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.

Stieglitz E, Lee A, Angus S, Davis C, Barkauskas D, Hall D Cancer Discov. 2024; 14(9):1590-1598.

PMID: 38867349 PMC: 11374478. DOI: 10.1158/2159-8290.CD-23-1376.


Suspected coexistence of perianal necrotizing sweet syndrome in chronic myelomonocytic leukemia: A case report.

Yu K, Li H, Wu J World J Gastrointest Surg. 2024; 16(4):1176-1183.

PMID: 38690058 PMC: 11056667. DOI: 10.4240/wjgs.v16.i4.1176.


A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Meyran D, Arfeuille C, Chevret S, Neven Q, Caye-Eude A, Lainey E Haematologica. 2024; 109(9):2908-2919.

PMID: 38385260 PMC: 11367243. DOI: 10.3324/haematol.2023.284103.